Clinical Trials
12 trialsNCT03691714 2026-06-01
Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
University of Cincinnati
Phase 2 Completed
NCT02997332 2026-03-23
MEDINDUCTION
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1 Terminated
NCT04954599 2025-10-07
Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI
Maastricht University Medical Center
Phase 1/2 Recruiting
NCT03019003 2025-09-16
Oral Decitabine (ASTX727) and Durvalumab in Recurrent and/or Metastatic Head and Neck Cancer Patients
Massachusetts General Hospital
Phase 1 Completed
NCT03518606 2025-01-15
MOVIE
UNICANCER
Phase 1/2 Completed
NCT06446570 2024-06-06
Phase II Study of Durvalumab(MEDI4736) + Tremelimumab in Pulmonary Sarcomatoid Carcinoma
Seoul National University Hospital
Phase 2 Completed
NCT05429866 2023-03-08
Immunological Variables Associated to ICI Toxicity in Cancer Patients
Jules Bordet Institute
Phase 2 Unknown
NCT04359199 2023-02-10
QUASAR
University of California, San Diego
Unknown
NCT03292250 2022-03-29
Korean Cancer Study Group: Translational bIomarker Driven UMbrella Project for Head and Neck (TRIUMPH), Esophageal Squamous Cell Carcinoma- Part 1 (HNSCC)]
Seoul National University Hospital
Phase 2 Completed
NCT03799744 2022-03-28
Safety,Tolerability,and Efficacy of VCN-01 With Durvalumab in R/M Head and Neck Squamous Cell Carcinoma
Institut Català d'Oncologia
Phase 1 Unknown
NCT03829007 2022-01-10
PINCH
Radboud University Medical Center
Phase 1/2 Completed
NCT03051906 2017-11-22
DUCRO-HN
Azienda Ospedaliero-Universitaria Careggi
Phase 1/2 Unknown